Loading...

PE anti-mouse IL-4 Antibody

Pricing & Availability
Clone
11B11 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
11B11_PE_1_051311
PMA+ionomycin-stimulated (6 hours, in presence of brefeldin A) Th2-polarized C57BL/6 CD4-positive cells were surface stained with CD3 APC and then intracellularly stained with IL-4 (11B11) PE (top) or Rat IgG1, κ PE isotype control (bottom).
  • 11B11_PE_1_051311
    PMA+ionomycin-stimulated (6 hours, in presence of brefeldin A) Th2-polarized C57BL/6 CD4-positive cells were surface stained with CD3 APC and then intracellularly stained with IL-4 (11B11) PE (top) or Rat IgG1, κ PE isotype control (bottom).
  • 11B11_PE_2_051311
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
504103 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
504104 100 µg 203€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Partially purified native mouse IL-4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).
Additional reported applications (for the relevant formats) include: immunoprecipitation16, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections8 and paraformaldehyde-fixed, saponin-treated frozen tissue sections6,7, and immunocytochemistry4.
Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.

Application References
  1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
  2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
  3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
  4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
  6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
  7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
  8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
  10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
  13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
  15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)
Product Citations
  1. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  2. Qu L, et al. 2022. Cell. 185:1728. PubMed
  3. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  4. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  5. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  6. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  7. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  8. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  9. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  10. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  11. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  12. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  13. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  14. Choi BJ, et al. 2023. Nat Commun. 14:1631. PubMed
  15. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  16. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  17. Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed
  18. Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed
  19. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  20. Wei H, et al. 2021. Malar J. 20:89. PubMed
  21. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  22. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  23. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  24. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  25. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  26. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  27. Amir M, et al. 2018. Cell Rep. 25:3733. PubMed
  28. Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed
  29. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  30. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  31. Wu G, et al. 2020. Br J Pharmacol. 177:5063. PubMed
  32. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  33. Kohu K, et al. 2009. J Immunol. 183:7817. PubMed
  34. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  35. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  36. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  37. Green CD et al. 2018. Developmental cell. 46(5):651-667 . PubMed
  38. Trompette A, et al. 2022. Mucosal Immunol. :. PubMed
  39. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  40. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
  41. Sawant D, et al. 2014. J Immunol. 192:2904. PubMed
  42. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  43. Coe D, et al. 2022. JCI Insight. 7:. PubMed
  44. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  45. Ikeda U, et al. 2010. Immunol Lett. 134:7. PubMed
  46. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  47. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  48. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  49. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  50. Chung NH, et al. 2022. Vaccine. 40:574. PubMed
  51. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  52. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  53. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  54. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  55. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  56. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  57. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  58. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  59. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  60. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  61. Choi J, et al. 2015. PLoS One. 10: e0138592. PubMed
  62. Xiao u, et al. 2015. J Immunol. 195: 4218 - 4227. PubMed
  63. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  64. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  65. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  66. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  67. Chan Y, et al. 2009. J Immunol. 183:7039. PubMed
  68. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  69. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  70. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  71. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  72. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  73. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
  74. Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed
  75. Nomura S, et al. 2019. Sci Rep. 9:17335. PubMed
  76. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  77. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  78. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  79. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_315317 (BioLegend Cat. No. 504103)
AB_315317 (BioLegend Cat. No. 504104)

Antigen Details

Structure
Cytokine; 15-19 kD (Mammalian)
Bioactivity
Differentiation of naïve CD4+ T cells to the TH2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells
Cell Sources
Mast cells, T cells, bone marrow stromal cells
Cell Targets
B cells, T cells, monocytes, endothelial cells, fibroblasts
Receptors
Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R
Cell Type
Tregs
Biology Area
Immunology
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294.
3. Dullens H, et al. 1991. In vivo 5:567.
4. Paul W. 1991. Blood 77:1859.

Regulation
Upregulated by IL-2, platelet activating factor; downregulated by TGF-β
Gene ID
16189 View all products for this Gene ID
UniProt
View information about IL-4 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 3    Revision Date: 07/11/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account